Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Gill, David Michael
Agarwal, Neeraj
Hahn, Andrew W.
Johnson, Eric
Poole, Austin
Carroll, Emma
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Molecular characterization of circulating tumor cells (CTC) from castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA)
    Attard, Gerhardt
    Swennenhuis, Joost
    Olmos, David
    Reid, Alison
    Coumans, Frank
    Vickers, Elaine
    Oommen, Nikhil Babu
    Thompson, Emilda
    A'Hern, Roger
    Cox, Michael
    Molina, Arturo
    Terstappen, Leon
    De Bono, Johann
    CANCER RESEARCH, 2009, 69
  • [22] Evidence for circulating tumor cell (CTC) alkaline phosphatase (AP) expression in men with bone-metastatic castration-resistant prostate cancer (CRPC) during abiraterone acetate treatment
    Armstrong, Andrew J.
    Bitting, Rhonda Lynn
    Kemeny, Gabor
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [23] Circulating tumor cells (CTC) in patients with metastatic castration-resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy
    Fleisher, M.
    Danila, D. C.
    Leversha, M.
    Rathkopf, D.
    Slovin, S.
    Anand, A.
    Koscuiszka, M.
    Haqq, C.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [25] Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study.
    Ryan, C. J.
    Harzstark, A. L.
    Lin, A. M.
    Fong, L.
    Grycz, K.
    Szmulewitz, R. Z.
    Weinberg, V. K.
    Molina, A.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
    Martini, Alberto
    Fallara, Giuseppe
    Ploussard, Guillaume
    Malavaud, Bernard
    LANCET ONCOLOGY, 2023, 24 (10): : 1056 - 1057
  • [27] Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Titus, Mark Anton
    Wen, Sijin
    SanMiguel, Aileen
    Hoang, Anh
    De Haas-Amatsaleh, Angela
    Perabo, Frank
    De Phung
    Troncoso, Patricia
    Ouatas, Taoufik
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [29] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [30] Predictors of outcome to post-docetaxel abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (p)
    Ochoa de Olza, M.
    Font, A.
    Sala, N.
    Beltran, M.
    Barretina, P.
    Etxaniz, O.
    Indacoechea, A.
    Hernandez, A.
    Navarro, V.
    Germa, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S701
12345